THERAPY DOSSIER · th-8caeb03f7cf6

Plant-made recombinant cholera toxin B subunit (CTBp)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01109914 ↗PHASE4completed

Immune Response After Inactivated Oral Cholera Vaccine (Dukoral, WC/rBS) in Renal Transplant Recipients

Kidney Transplantation · Immunity

Enrolment: 51 · Results not recorded

NCT02556996 ↗PHASE3completed

Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine (ETEC/rCTB) in Prevention of Diarrhea in Egyptian Infants and Young Children

Diarrhea

Enrolment: 356 · Results not recorded

NCT00820144 ↗PHASE1completed

Functional Exploration of the Immune Response Using the B-subunit of Cholera Toxin Administered by Mucosal Way in Healthy Adult Volunteers

Infection

Enrolment: 40 · Results not recorded

NCT07270796 ↗PHASE1not yet recruiting

A Phase I Trial to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine (Dukoral active control)

Cholera Vaccination Reaction

Enrolment: 60 · Results not recorded

NCT00709410 ↗NAcompleted

Mass Oral Cholera Vaccination (rBS-WC) in High-risk Populations in Zanzibar

Cholera · Diarrhea

Enrolment: 51151 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27805617 ↗2016Reported benefit

Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.

MouseChemical/toxinC57BL/6femaleOral

Model: Dextran sodium sulfate induced acute colitis, plus an azoxymethane/dextran sodium sulfate colitis-associated cancer model

Oral CTBp protected against colonic mucosal damage with reduced body weight loss, lower histopathological scores and blunted inflammatory cytokine escalation, induced wound healing genes, and reduced disease severity and tumourigenesis in the azoxymethane/dextran sodium sulfate model.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…